Biotech in fase clinica che sviluppa spray nasali per la protezione dalle infezioni respiratorie.
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Funding round Leyden Labs secured €30 million in equity from the EIC Fund and Invest-NL to advance clinical development of its pan-influenza nasal spray. | $34.8M |
| Feb 2022 | Series B Amsterdam biotech Leyden Labs raised a 140M dollar Series B led by Casdin Capital and GV, with SoftBank Vision Fund 2, Invus and F-Prime Capital. | $124.2M |
| Mar 2021 | Series A Amsterdam biotech Leyden Labs raised a EUR40M Series A led by GV, with F-Prime Capital, Casdin Capital and Brook Byers. | $40M |